Chairman and Managing Director Glenn Saldanha said on Monday that the company has several assets under development, including ...

A warning letter is a serious communication from the USFDA that signifies a potential risk to public health or safety due to ...

Glenmark’s outlicensing deal with AbbVie for a novel drug for blood cancer under development sets a new course for the ...

By Kashish Tandon (Reuters) -Shares of India's Glenmark Pharmaceuticals jumped 10% to a record high on Friday, a day after ...

With the stock currently trading at Rs 2,225.80, Glenmark Pharma has shown a positive movement of 2.05% in today's session.

Glenmark Pharmaceuticals Ltd is up for a third straight session today. The stock is quoting at Rs 2214.7, up 1.54% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is ...

India's Glenmark Pharmaceuticals said on Thursday its innovation arm, Ichnos Glenmark Innovation (IGI), and AbbVie have ...

Glenmark Pharma share price today: Shares of Glenmark Pharma surged 10 per cent, recording a 52-week high of ₹2,094.40 on ...

Glenmark Pharmaceuticals Ltd.’s licensing pact with AbbVie Inc. for its blood cancer drug is boosting optimism over Indian ...

With a $2-billion cancer drug deal in its pocket, Glenmark’s licensing agreement with AbbVie not only unlocks a potential ...

Promoter group entities of VIP Industries have agreed to sell up to 58 per cent stake in the luggage company to a consortium of Multiples private equity for ₹3,200 crore, according to an exchange ...

HSBC and Axis Capital are more bullish on its transformative impact and future growth prospects for Glenmark, while Nuvama ...